Shantou Institute of Ultrasonic Instrument
301602
Hubei Sinophorus Electronic Materials
688545
Pansoft
300996
4
Jiayu Holding
300117
5
Wuxi Taclink Optoelectronics Technology
688205
US Stock MarketDetailed Quotes
ASND Ascendis Pharma A/S
- 126.450
- -4.610-3.52%
Trading Jan 22 13:32 ET
7.56BMarket Cap-16.25P/E (TTM)
131.700High123.020Low350.05KVolume131.450Open131.060Pre Close43.91MTurnover0.59%Turnover RatioLossP/E (Static)59.81MShares161.00052wk High-74.51P/B7.51BFloat Cap111.09052wk Low--Dividend TTM59.37MShs Float183.980Historical High--Div YieldTTM6.62%Amplitude11.920Historical Low125.429Avg Price1Lot Size
About Ascendis Pharma A/S Company
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
Company Profile
SymbolASND
Company NameAscendis Pharma A/S
Listing DateJan 28, 2015
Issue Price18.00
Founded2006
CEOMr. Jan Moller Mikkelsen
MarketNASDAQ
Employees879
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
AddressTuborg Boulevard 12
CityHellerup
ProvinceCapital Region
CountryDenmark
Zip Code2900
Phone45-70-22-22-44
Company Executives
- Name
- Position
- Salary
- Jan Moller Mikkelsen
- President, Chief Executive Officer and Director
- --
- Scott T Smith
- Executive Vice President and Chief Financial Officer
- --
- Michael Wolff Jensen
- Executive Vice President and Chief Legal Officer
- --
- Camilla Harder Hartvig
- Executive Vice President and Global Chief Commercial Officer
- --
- Lotte Sonderbjerg
- Executive Vice President and Chief Administrative Officer
- --
- Peter Rasmussen
- Vice President, Finance and Principal Accounting Officer
- --
- Flemming Steen Jensen
- Executive Vice President, Product Supply and Quality
- --
- Dr. Stina Singel, M.D.
- Executive Vice President and Head of Clinical Development, Oncology
- --
- Dr. Kennett Sprogoe, PhD
- Executive Vice President and Head of Innovation and Research
- --
- Dr. Albert Cha, M.D.,PhD
- Chairman of the Board
- --
- Lisa Bright
- Independent Director
- --
- William Carl Fairey
- Independent Director
- --
- Lars Holtug
- Independent Director
- --
- Siham Imani
- Independent Director
- --
Trending Stocks
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace